Atara Biotherapeutics Faces Securities Lawsuit Alleging Fraudulent Statements
A class action lawsuit was filed against Atara Biotherapeutics (NASDAQ: ATRA) alleging securities fraud related to misleading statements about the company's drug development and regulatory prospects. The case affects investors who held shares between May 20, 2024, and January 9, 2026.
Tickers: $ATRA
Topics: clinical trials FDA approval lawsuit securities fraud